148 related articles for article (PubMed ID: 37097811)
1. Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy.
Fan R; Chen C; Mu M; Chuan D; Liu H; Hou H; Huang J; Tong A; Guo G; Xu J
ACS Nano; 2023 May; 17(10):9126-9139. PubMed ID: 37097811
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
Hu J; Jiang C; Zheng M; Guo Y; Tang X; Ren J; Lu D; Yu L; Gan W; Liu S; Tong A; Yang H
Am J Transl Res; 2019; 11(8):5183-5196. PubMed ID: 31497233
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
4. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
5. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
[TBL] [Abstract][Full Text] [Related]
6. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
7. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
Front Oncol; 2020; 10():1527. PubMed ID: 32984002
[TBL] [Abstract][Full Text] [Related]
8. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.
Liu B; Ji Q; Cheng Y; Liu M; Zhang B; Mei Q; Liu D; Zhou S
J Nanobiotechnology; 2022 Mar; 20(1):161. PubMed ID: 35351131
[TBL] [Abstract][Full Text] [Related]
9. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
10. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
12. Targeting T cells with bispecific antibodies for cancer therapy.
Lum LG; Thakur A
BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
14. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
15. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM.
Feng S; Liang X; Li J; Wang Z; Zhang H; Dai Z; Luo P; Liu Z; Zhang J; Xiao X; Cheng Q
Front Immunol; 2022; 13():992855. PubMed ID: 36248827
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
Liu T; Zhu C; Chen X; Guan G; Zou C; Shen S; Wu J; Wang Y; Lin Z; Chen L; Cheng P; Cheng W; Wu A
Neuro Oncol; 2022 Jul; 24(7):1113-1125. PubMed ID: 35148413
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
20. Iron oxide nanoparticles loaded with paclitaxel inhibits glioblastoma by enhancing autophagy-dependent ferroptosis pathway.
Chen H; Wen J
Eur J Pharmacol; 2022 Apr; 921():174860. PubMed ID: 35278406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
